EUROPLUS™ ANCA BIOCHIP mosaic: PR3 and MPO antigen microdots improve the laboratory diagnostics of ANCA-associated vasculitis

Damoiseaux, Jan; Steller, Ulf; Buschtez, Michael; Vaessen, Mia; Rosemann, Anke; Paassen, Pieter van; Stöcker, W.; Fechner, Kaï; Tervaert, Jan Willem Cohen

doi:10.1016/j.jim.2009.07.001

Cited by 30 publications

(19 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nature Reviews | Rheumatology biochip and microbead technology 49,50 , and automatic pattern recognition devices have become available to support the evaluation of IIF (REFS 51,52). However, innovations in ANCA detection have not only been limited to IIF and ELISAs; alternative solid-phase assays are also now being marketed, including dot and line immunoassays 53 , fluorescent-enzyme immunoassays (FEIA) 54,55 , addressable-laser-bead immunoassays (ALBIA) 56,57,58,59 and chemiluminescent immunoassays (CLIA) 60,61 .…”

Section: Anca Interpretation Can Be Improved With Test-results Intervalsmentioning

confidence: 99%

Revised 2017 international consensus on testing of ANCAs in granulomatosis with polyangiitis and microscopic polyangiitis

et al. 2017

Self Cite

View full text Add to dashboard Cite

| Anti-neutrophil cytoplasmic antibodies (ANCAs) are valuable laboratory markers used for the diagnosis of well-defined types of small-vessel vasculitis, including granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA). According to the 1999 international consensus on ANCA testing, indirect immunofluorescence (IIF) should be used to screen for ANCAs, and samples containing ANCAs should then be tested by immunoassays for proteinase 3 (PR3)-ANCAs and myeloperoxidase (MPO)-ANCAs. The distinction between PR3-ANCAs and MPO-ANCAs has important clinical and pathogenic implications. As dependable immunoassays for PR3-ANCAs and MPO-ANCAs have become broadly available, there is increasing international agreement that high-quality immunoassays are the preferred screening method for the diagnosis of ANCA-associated vasculitis. The present Consensus Statement proposes that high-quality immunoassays can be used as the primary screening method for patients suspected of having the ANCA-associated vaculitides GPA and MPA without the categorical need for IIF, and presents and discusses evidence to support this recommendation.NATURE REVIEWS | RHEUMATOLOGY VOLUME 13 | NOVEMBER 2017 | 683 CONSENSUS STATEMENT © 2 0 1 7 M a c m i l l a n P u b l i s h e r s L i m i t e d , p a r t o f S p r i n g e r N a t u r e . A l l r i g h t s r e s e r v e d .Given the improvements in antigen-specific immuno assays, the international consensus on the testing of ANCAs in small-vessel vasculitis seems in need of updating [7][8][9][10] . In this manuscript, a revised 2017 international consensus is proposed by a group of international experts (from North and Central America, Australia, Europe and Asia) in the ANCA field. This Consensus Statement highlights the value of ANCA testing as a tool for diagnosis (but not follow-up) of GPA and MPA and gives a historical perspective of ANCAs in small-vessel vasculitis. This Consensus Statement does not, however, present evidence-based guidelines or a meta-analysis. MethodsThis Consensus Statement was prepared by a group of experts from four European laboratories (X.B., J.D., N.R., J.W.C.T. and E.C.) in person and by correspondence. The draft was circulated to each contributor and modified, and the resulting document was distributed by e-mail to 16 experts from four continents, selected based on their expertise and knowledge in clinical and/or laboratory aspects of AAV. This revised document resulted in a second round of discussions and revisions. The final document was returned to all contributors for ratification.The Consensus Statement is based on the results of a multicentre European Vasculitis Study Group (EUVAS) evaluation of the value of IIF versus antigen-specific immunoassays for ANCA detection 6,11,12 . This study, which showed a large variability between different IIF methods and a good diagnostic performance of PR3-ANCA and MPO-ANCA immunoassays 6 , indicated that the 1999 international consensus on ANCA testing for AAV needed revision. When the consensus was put toget...

show abstract

Section: Anca Interpretation Can Be Improved With Test-results Intervalsmentioning

confidence: 99%

Revised 2017 international consensus on testing of ANCAs in granulomatosis with polyangiitis and microscopic polyangiitis

et al. 2017

Self Cite

View full text Add to dashboard Cite

show abstract

“…Formalin fixation of neutrophils destroys the antigenicity of multiple (irrelevant) antigens, including interfering ANA as well as multiple antigens other than PR3 or MPO, and reveals the shift in staining pattern from P-ANCA on ethanol-fixed neutrophils to C-ANCA on formalin-fixed neutrophils. As mentioned, the biochip technology enables to combine both substrates in a single incubation (Damoiseaux et al, 2009b). The usefulness of formalin-fixation is already a longstanding discussion (Bird, 1999).…”

Section: Discussionmentioning

confidence: 99%

“…This biochip technology is a composite substrate of ethanol-and formalin-fixed granulocytes, Hep-2 cells and monkey liver (both for detecting potential interference of ANA), and microdots consisting of the PR3 and MPO antigens. This method has a very high concordance with a multi-test reference method based on IIF, direct ELISA, and capture ELISA (Damoiseaux et al, 2009b …”

Section: Fig 2 Pr3-and Mpo-anca Detection By Antigen-specific Assaysmentioning

confidence: 93%

ANCA Diagnostics in Clinical Practice: New Developments

Damoiseaux¹,

Austen²,

Tervaert³

2011

Advances in the Diagnosis and Treatment of Vasculitis

Self Cite

View full text Add to dashboard Cite

“…6 Although, because of improvement of the antigen-specific assays, the necessity of IIF screening is being disputed, 13 multiparametric IIF very elegantly combines the cellular-and antigen-specific substrates and thereby follows the international consensus. 9,11,14 The improvements achieved in the detection of MPO-and PR3-ANCA are primarily based on the methodology used for coating the antigen to the solid phase. Binding of the antigen via a capturing monoclonal antibody, ie, second-generation immunoassay, or via a peptide-linker, ie, third-generation immunoassay, has been proven superior to direct coating of the antigen, ie, first-generation immunoassay.…”

Section: Multiparametric Autoantibody Diagnostics In Systemic Autoimmmentioning

confidence: 99%

Multiparametric autoimmune diagnostics: recent advances

Damoiseaux¹

2016

PLMI

Self Cite

View full text Add to dashboard Cite

Autoimmune diagnostics in a routine clinical laboratory is constantly challenged by the discovery of new autoantibodies and technical innovations in the immunoassays applied. These challenges are, in particular, combined in the multiparametric immunoassays. Appropriate positioning of multiparametric immunoassays within the laboratory requires integrated knowledge of the clinical performance of the test system for each individual antigen, the conditions prescribed in disease criteria and/or guidelines, and the demands of the clinicians. This review provides a summary of the multiparametric immunoassays available, as well as the applications and restrictions in routine clinical practice.

show abstract

EUROPLUS™ ANCA BIOCHIP mosaic: PR3 and MPO antigen microdots improve the laboratory diagnostics of ANCA-associated vasculitis

Cited by 30 publications

References 28 publications

Revised 2017 international consensus on testing of ANCAs in granulomatosis with polyangiitis and microscopic polyangiitis

Revised 2017 international consensus on testing of ANCAs in granulomatosis with polyangiitis and microscopic polyangiitis

ANCA Diagnostics in Clinical Practice: New Developments

Multiparametric autoimmune diagnostics: recent advances

Contact Info

Product

Resources

About